Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Clinical trial NCT01221077 · COMPLETED
Trial details
- NCT number
- NCT01221077
- Sponsor
- Astellas Pharma Inc
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-04-08
- Primary completion
- 2013-03-01
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.